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Introduction
Among adhesion molecule families, integrins are striking for 
the diversity of the ligands they recognize, and the types of 
adhesion that they mediate. This diversity is reflected not only 
in the large number of 18  and 8  subunits, but also in the low 
sequence identity of 22% among  subunits belonging to six 
different integrin families (Fig. S1 A). Despite crystal structures 
for three of the 24 different integrin heterodimers (Xiao et al., 
2004; Zhu et al., 2008; Xiong et al., 2009; Xie et al., 2010), 
much of the structural basis for integrin functional diversity 
remains to be described.
The 4 integrin family includes one of the most broadly 
expressed integrins, 41, and two of the most specialized inte-
grins, 47 and 91. Unique among integrins, 47 is a homing 
receptor  that  targets  lymphocytes  and  specific  leukocyte   
subsets in the bloodstream to mucosal tissues, especially the 
gut (Springer, 1994). The primary ligand for 47-mediated 
homing is mucosal adhesion molecule-1 (MAdCAM-1), an ad-
dressin with two immunoglobulin superfamily (IgSF) domains 
and a mucin-like stalk that is specifically expressed on Peyer’s 
patch high endothelial venules and postcapillary venules in 
lamina propria (Streeter et al., 1988; Berlin et al., 1993; Briskin 
et al., 1993). In the multistep model of leukocyte binding to en-
dothelium and migration into tissues, it is generally selectins 
that mediate tethering and rolling on the vessel wall and inte-
grins  that  mediate  subsequent  firm  adhesion  and  migration 
(Springer, 1994; von Andrian and Engelhardt, 2003). The larg-
est exception to this rule is integrin 47, which clearly mediates 
rolling as well as firm adhesion in vivo as it functions as a hom-
ing receptor (Bargatze et al., 1995).
Integrin  41  is  expressed  on  many  connective  tissue 
cells, as well as on lymphocytes and monocytes. 41 and its 
ligand,  vascular  cell  adhesion  molecule-1  (VCAM-1),  have 
roles in vascular and heart development (Bouvard et al., 2001), 
atherosclerosis (Cybulsky and Gimbrone, 1991), co-stimulation 
of immune responses, and lymphocyte and monocyte traffick-
ing  in  inflammation  (von  Andrian  and  Engelhardt,  2003). 
VCAM-1 has seven IgSF domains, the first two of which are 
25% identical to those of MAdCAM-1. 41 and 47 also bind   
fibronectin through an LDV motif in the alternatively spliced 
connecting III segment (IIICS) distinct from the RGD motif in 
T
he  lymphocyte  homing  receptor  integrin  47  is 
unusual for its ability to mediate both rolling and 
firm adhesion. 41 and 47 are targeted by ther-
apeutics approved for multiple sclerosis and Crohn’s 
disease. Here, we show by electron microscopy and 
crystallography how two therapeutic Fabs, a small mol-
ecule (RO0505376), and mucosal adhesion molecule-1   
(MAdCAM-1) bind 47. A long binding groove at the 
4–7  interface  for  immunoglobulin  superfamily  do-
mains differs in shape from integrin pockets that bind   
Arg-Gly-Asp motifs. RO0505376 mimics an Ile/Leu-Asp 
motif in 4 ligands, and orients differently from Arg-Gly-
Asp mimics. A novel auxiliary residue at the metal ion– 
dependent adhesion site in 47 is essential for bind-
ing  to  MAdCAM-1  in  Mg
2+  yet  swings  away  when 
RO0505376 binds. A novel intermediate conformation 
of the 47 headpiece binds MAdCAM-1 and supports 
rolling adhesion. Lack of induction of the open head-
piece  conformation  by  ligand  binding  enables  rolling 
adhesion to persist until integrin activation is signaled.
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Structural studies on integrins have revealed three overall   
conformational states, and correlated them with ligand bind-
ing or affinity state (Fig. 1, A, B, and D; Luo et al., 2007). 
Crystal,  small-angle  x-ray  scattering  (SAXS),  as  well  as  EM   
studies on liganded and unliganded integrin ectodomains or head-
pieces, and on function-perturbing Fab-bound integrins using   
V3, IIb3, 51, and X2, have shown that the bent and the   
extended-closed headpiece conformations have low affinity for   
ligand, whereas the extended-open headpiece conformation 
has high affinity (Takagi et al., 2002, 2003; Mould et al., 2003; 
Luo et al., 2004; Xiao et al., 2004; Iwasaki et al., 2005; Springer 
et al., 2008; Zhu et al., 2008, 2010; Chen et al., 2010; Xie   
et al., 2010). Although not all groups have seen integrin exten-
sion (Adair et al., 2005; Xiong et al., 2009), extension and head-
piece opening are being increasingly described as important in 
activation by multiple independent groups (Iwasaki et al., 2005; 
Askari et al., 2010; Kamata et al., 2010; Ye et al., 2010).
It has been hypothesized that rolling adhesion is mediated 
by a closed-headpiece, low-affinity state of 47, whereas firm 
adhesion is mediated by an open-headpiece, high-affinity state 
of 47 (Chen et al., 2003). Both types of adhesion require an 
intact metal ion–dependent adhesion site (MIDAS) in the I do-
main that is hypothesized to hold an Mg
2+ ion that coordinates 
to a critical Asp in IgSF domain 1 of MAdCAM-1 (Newham   
et al., 1997; Green et al., 1999). Metal binding sites on either side 
of the MIDAS, the synergistic metal ion binding site (SyMBS), 
and adjacent to MIDAS (ADMIDAS), have opposing, bipolar 
effects (Chen et al., 2003). SyMBS mutations result in rolling 
adhesion, and ADMIDAS mutations result in firm adhesion, no 
matter whether Ca
2+, Ca
2+/Mg
2+, Mg
2+, or Mn
2+ are present.
Studies on RGD-binding integrins V3, IIb3, and 51 
have  shown  that  ligand  binding  induces  headpiece  opening 
(Takagi et al., 2002, 2003; Mould et al., 2003; Xiao et al., 2004; 
Zhu et al., 2010). This is hypothesized to be incompatible with roll-
ing adhesion; if MAdCAM-1 binding induced the open-headpiece 
Fn3 domain 10 of fibronectin recognized by integrins V3, 
IIb3, and 51. 41 binds better to VCAM-1 and fibronectin 
than to MAdCAM-1, and 47 binds to MAdCAM-1 better than 
or similarly to VCAM-1 and fibronectin (Andrew et al., 1994; 
Strauch et al., 1994; Newham et al., 1997; Day et al., 2002).
Antagonists of 4 integrins represent an important new 
class of therapeutics for autoimmune diseases (Davenport and 
Munday, 2007). The humanized antibody natalizumab to the 
integrin 4 subunit is approved for both relapsing multiple scle-
rosis (MS) and Crohn’s disease (Miller et al., 2003; Sandborn   
et al., 2005). However, use of natalizumab is limited by progres-
sive multifocal leukoencephalopathy, caused by a polyoma-like 
virus that is latent in the majority of adults and can emerge after 
suppression of the adaptive immune response (Major, 2010).
Greater selectivity may be achieved by only targeting 
47 or 41. Act-1 antibody (Lazarovits et al., 1984), which 
binds 47 and not 41 or E7 (Schweighoffer et al., 1993), 
disrupts the interaction between 47 and MAdCAM-1, and 
rapidly resolves chronic colitis in an animal model (Hesterberg 
et al., 1996). Humanized Act-1, vedolizumab, demonstrates 
efficacy in clinical trials for ulcerative colitis and Crohn’s dis-
ease (Hesterberg et al., 1996; Feagan et al., 2005; Davenport 
and Munday, 2007; Feagan et al., 2008; Soler et al., 2009). In-
terestingly, Act-1/vedolizumab selectively blocks 47 bind-
ing to MAdCAM-1 and fibronectin but not to VCAM-1 (Soler 
et al., 2009).
Small molecule antagonists of 41/47 are in trials for 
inflammatory bowel disease, asthma, and multiple sclerosis 
(Davenport and Munday, 2007). The most widely developed 
class of antagonist is based on a phenylalanine moiety with a 
free carboxyl group, e.g., RO0505376 (Davenport and Munday, 
2007). A structure of a small molecule antagonist bound to 47 
would be enormously useful for development of 47-selective 
and 41-selective antagonists for inflammatory bowel and cen-
tral nervous system diseases, respectively.
Figure 1.  Schematic of integrin domain organization and conformational states. The pink loop and black bar in B–D represent the 6-7 loop and 7-helix 
of the I domain, respectively. Broken lines symbolize lower  leg flexibility. The intermediate headpiece state is shown here for the first time.133 Structural specializations of 47 and rolling adhesion • Yu et al.
at 3.5 and 3.6 Å. Phases were improved by multicrystal aver-
aging using lattices with two or four headpiece–Fab com-
plexes per asymmetric unit (Table 1). Final structures at 3.15 
and 3.1 Å resolutions are well refined with R free of 25.1 and 
23.1%, respectively.
The crystal structure contains the 4 -propeller and thigh 
domains, the 7 I and hybrid domains, and Fab (Figs. 2 A  
and S2). The 7 PSI and I-EGF1 domains are present in the 
crystallization construct and in crystals, as confirmed by the 
molecular weight of the 7 subunit in SDS-PAGE. However, 
weak density for the PSI domain and lack of density for the   
I-EGF1 domain suggest flexibility at their connections to the   
N and C termini of the 7 hybrid domain, respectively (Fig. 2 A).   
Superposition  of  IIb3  headpieces  in  the  closed  and  open 
conformations demonstrates that the 47 headpiece is in the 
closed conformation (Fig. 2 B).
Whereas many integrins that lack I domains contain a 
furin cleavage site in the  subunit calf-2 domain, 4 is unusual 
conformation of 47, this would be predicted to give firm 
adhesion. Here, we investigate the specializations that enable 
47 to mediate both rolling adhesion and firm adhesion. We 
describe EM and crystal structures of the 47 headpiece in 
complex with Act-1 and natalizumab Fab and a ligand-mimetic 
antagonist. The shape of the ligand-binding pocket differs from 
previously described integrins, and is specialized for binding 
IgSF domains. Other specialized structural features include a 
novel intermediate conformation of the headpiece that is impor-
tant in rolling adhesion, and an auxiliary MIDAS residue that is 
important for binding to MAdCAM-1 in Mg
2+.
Results
Overall 47 headpiece structure
A headpiece fragment of 47 co-crystallized with Act-1 Fab 
and diffracted to 3.15 Å (Fig. 2 and Table 1). The structure was 
solved by multi- and single-wavelength anomalous diffraction 
Figure 2.  The 47 headpiece crystal structure. (A) Overall structure of the 47 headpiece complex with Act-1 Fab. Ca
2+ and Mg
2+ ions are silver and 
orange spheres, respectively. Disulfide bonds are shown in orange and glycans with white carbons are shown as sticks. (B) Superposition of the closed 
(white; Zhu et al., 2008) and open (light blue; Springer et al., 2008) headpiece of IIb3 on 47 (colored domains). (C and D) Two distinct examples of 
the -propeller domain (cyan) interface with the thigh domain (wheat), shown in the same orientation. FG and GG loops are hot pink. (E) Superposition 
of the two most dissimilar 47 molecules. (F and G) The interface between the I (orange) and hybrid (green) domains in closed conformations of 47 (F)   
and IIb3 (G).JCB • VOLUME 196 • NUMBER 1 • 2012   134
hybrid domain residue 441 and forms a -cation bond to res-
idue  Phe-443.  Furthermore,  the  aliphatic  portion  of  the   
I Lys-346 side chain is buried by the side chain of Leu-441 
in the hybrid domain. Moreover, the side chain of I residue 
Tyr-131  hydrogen  bonds  to  the  backbone  of  residue  444,   
and the Tyr-131 and Phe-443 side chains pack at right angles   
to one another, optimizing interaction of their quadrupoles 
(Chakrabarti and Bhattacharyya, 2007). An interesting inter-
action with the hybrid domain is mediated by the N-linked 
glycan attached to I residue Asn-260 (Fig. 2 F). This N-linked 
glycan covers one flank of the hybrid domain, and its first   
N-acetyl  glucosamine  residue  hydrogen  bonds  to  Ser-444 
and Glu-446 (Fig. 2 F).
In IIb3, Arg-352, the last residue of the I domain, is 
key in the I hybrid domain interface and gives it a flatter shape 
than in 7 (Fig. 2 G). 7 Lys-346 and 3 Arg-352 approach the 
same part of the I hybrid interface from different directions 
and give it a different shape. Another difference is the lack of a 
glycosylation site in 3 equivalent to that at N260 in 7. The di-
rection of hybrid domain swing-out is such that even upon par-
tial opening, the hybrid domain moves away from I residues 
N260 and K346, isolating them from the interdomain interface. 
In contrast, in swing-out in the 3 subunit, Arg-352 as the last 
I residue moves along with the hybrid domain, and reorients 
(Xiao et al., 2004).
for lacking such a site and containing a furin cleavage site in its 
thigh domain. The furin site was deleted in the crystallization 
construct with an 4 R558A mutation, and lack of proteolytic 
processing of 4 was confirmed by SDS-PAGE.
Despite mutational abolition of cleavage of the FG loop, 
different examples of 47 molecules in crystal lattices show 
up to a 17° difference in orientation at the -propeller–thigh   
interface (Fig. 2 E). The FG loop forms a long, flexible bumper-
like  interface  with  the  -propeller  domain,  allowing  it  to 
move  in  concert  with  change  in  orientation  between  the   
-propeller and thigh domains that may be important in roll-
ing adhesion (Fig. 2, C and D). During reorientation of the 
-propeller and thigh domains by torsion of the thigh A strand   
(Fig. 2 C), which can result in separation into A and A strands 
(Fig. 2 D), remodeling of the FG and GG loop segments 
prevents clashes between the two domains and enables main-
tenance of the hydrogen bonds between the A and G (Fig. 2 C) 
or A and G  strands (Fig. 2 D).
The interface between the I and hybrid domains ap-
pears unusually stable in 47. Interdomain orientation var-
ied only 4 ± 2° (mean and SD) among four independent 47 
molecules (Fig. 2 E). This rigid orientation was enforced by 
hydrogen bonds that were invariant among the four examples 
of 47 molecules (Fig. 2 F). Lys-346 has a key role in the 
interface. This I residue hydrogen bonds to the backbone of 
Table 1.  X-ray diffraction data and refinement
Criteria Native 
lattice A
Se-SAD 
lattice A
Se-MAD  
lattice B
RO0505376 
lattice C
Se peak Se inflection Se remote
Wavelength (Å) 1.00695 0.97945 0.97945 0.9796 0.94957 1.03337
Space group P21 P21 P21 P21
Cell a, b, c (Å) 137.8, 122.7, 
158.1
136.9, 121.8, 157.8 158.4, 123.2, 240.6 127.6, 123.5, 154
, , g (º) 90, 115.4, 90 90, 115.4, 90 90, 101.8, 90 90, 112.6, 90
Resolution (Å) 50-3.15 50-3.6 50-3.5 50-3.1
Reflections (total/unique) 310,175/ 
82,079
410,287/ 
105,656
873,259/ 
114,453
433,115/ 
114,453
433,092/ 
114,412
286,405/ 
79,083
Completeness (%) 99.3/99.5
a 98.9/99.0
a 99.9/99.9
a 99.9/99.9
a 99.9/99.8
a 98.8/97.8
a
I/s (I) 10.3/1.9
a 7.7/2.1
a 15.6/3.5
a 10.1/1.9
a 10.0/2.2
a 5.4/1.6
a
Rmerge (%)
b 8.9/91.5
a 13.0/70.2
a 11.5/64.0
a 12.0/73.1
a 10.7/60.2
a 16.1/84.5
a
Refinement
Rwork
c 0.220 0.197
Rfree
d 0.251 0.231
RMSD
Bond (Å) 0.003 0.005
Angle (Å) 0.689 0.791
Complex/asymmetric unit 2 2 4 2
Ramachandran (percent-
age favored/allowed/
outlier)
e
91.4/8.0/0.6 91.8/7.6/0.6
PDB accession no. 3V4P 3V4V
aNumbers correspond to the last resolution shell.
bRmerge = h i |Ii (h)  < I(h) > |/h i Ii (h), where Ii (h) and < I(h) > are the ith and mean measurement of the intensity of reflection h.
cRwork = h || Fobs (h)|  | Fcalc(h)||/ h | Fobs (h)|, where Fobs (h) and Fcalc (h) are the observed and calculated structure factors, respectively. No I/ cutoff   
was applied.
dRfree is the R value obtained for a test set of reflections consisting of a randomly selected 5% subset of the data set excluded from refinement.
eResidues in favorable, allowed, and outlier regions of the Ramachandran plot as reported by MOLPROBITY (Davis et al., 2007).135 Structural specializations of 47 and rolling adhesion • Yu et al.
are named after the  strands they connect, and the -sheet, 
i.e., propeller blade, in which they are present. Each blade has 
four antiparallel  strands in a W topology, where each stroke 
of the letter W corresponds to one  strand. The propeller has 
seven blades, W1–W7. The 4 -propeller W1 4-1 loop, 
which connects W1 and W2, contains a disulfide bond that is 
absent in IIb, V, and X (Fig. 4 A). The W1 4-1 loop forms 
important contacts with two adjacent loops that help form the   
47 ligand-binding pocket, the W2 2-3 loop, and the W2 
4-1 loop (Fig. 4 A). The lengths, conformations, and locations 
on the -propeller surface of these three loops differ greatly 
among 4, V, IIb, and X (Fig. S1, B–D; and Fig. S2 A).  
The short W3 2-3 loop, in the center of the ligand-binding 
site (Fig. 4 A), is the only loop with a well-conserved sequence 
and backbone (Figs. S1 and S2). However, because of its sur-
roundings, its Tyr-187 side chain differs from Tyr-190 in IIb 
in both being higher on the 4 ligand-binding wall and further 
from the  subunit wall, helping to create a wider crevice in 
47 (Fig. 4, B and C). The W3 4-1 loop also differs mark-
edly in conformation between 4 and other known integrin 
subunits. In V and IIb, three residues in the W3 4-1 loop 
form a 310 helix, and the loop moves 6 Å toward the ligand-
binding pocket and narrows the crevice in the middle (Fig. 4, C 
and D). In 4, this loop contains no secondary structure and 
locates far from the binding interface (Fig. 4 B). Finally, the 
4 W4 2-3 loop (Fig. 4 A) is one residue shorter than in 
IIb and V and lacks the Trp-262 in IIb or Arg-248 in V that 
protrudes into the crevice (Fig. 4, B–D).
Act-1 Fab complex
Act-1 recognizes an extended, disulfide-bonded loop known as 
the specificity-determining loop (SDL) that projects from the   
7 I domain near its MIDAS at the interface with the 4  
-propeller domain (Fig. 2 A). The Fab contacts just the 7 subunit 
and buries a total solvent-accessible surface area of 1,300 Å
2.   
Most of the area on 7 is contributed by the SDL (88%)   
with the remainder centered at Ser-231 in the I domain 2-3 
loop (Figs. 2 A and 3 A). Residues 194–205 of the SDL are 
buried in a cleft formed by complementarity-determining re-
gions (CDRs) H1 and H3 of the heavy chain (Fig. 3 A). CDR   
L1  of  the  light  chain  forms  much  of  the  contact  with  the   
I domain 2-3 loop. The Fab interface is rich with hydrogen 
bonds to both integrin side chains and backbone. SDL residue 
Arg-200 has a prominent role at the center of the interface 
(Fig. 3 A). Furthermore, the 7 Arg-203 guanido group stacks 
between H3 residue Trp-104, which protrudes from CDR H3, 
and L1 residue Tyr-33 to form two -cation bonds (Fig. 3 A). 
Moreover, a basic patch on the SDL including residues Arg-
194, His-195, Arg-200, and Arg-203 is complemented by a 
negatively charged binding interface on the Fab, as shown by 
electrostatic surfaces (Fig. 3 B).
Ligand-binding site
The -propeller domain of 4 differs from those of the previ-
ously characterized IIb, V, and X integrins, particularly in 
the loops on the face of the -propeller domain that bind the   
I domain and form the ligand-binding site (Fig. 4). These loops 
Figure  3.  The  Act-1  Fab  complex.  (A)  The 
integrin–Fab  interface  showing  the  most  sig-
nificant side chains and their hydrogen bonds. 
(B) Open-book view of the Act-1–integrin com-
plex. The contact areas have dashed outlines. 
The approximate -propeller domain boundary 
with the I domain is also shown with dashed 
lines. The electrostatic surface (5 [red] to +5 
[blue] kT/e) was calculated using the Adaptive 
Poisson-Boltzmann Solver software plug-in for 
PyMOL (Baker et al., 2001).JCB • VOLUME 196 • NUMBER 1 • 2012   136
are similar to those in closed IIb3 (Fig. 5 B) and not in open 
IIb3 (Fig. 5 D). These findings agree with the closed position 
of the 7 hybrid domain, and confirm that the 7 I domain adopts 
the closed conformation.
Most interestingly, the 7 subunit, unlike 3, has an extra 
Asp residue at the MIDAS (Fig. 5, A and B). Density for the 
side chain of Asp-271 clearly shows two conformations, one of 
which forms a direct coordination to the MIDAS Mg
2+ with an 
O–Mg
2+ distance of 2.2 Å (Figs. 5 A and S3). An extra Glu side 
chain is also nearby the ADMIDAS, Glu-354, but does not ap-
pear to be close enough to form a direct coordination.
The  functional  significance  of  residues  Asp-271  and 
Glu-354 was tested mutationally and compared with represen-
tative SyMBS, MIDAS, and ADMIDAS mutations (Fig. 6).   
As described previously (Chen et al., 2003) in Ca
2+ or Ca
2+ + 
Mg
2+, wild-type 47 mediates rolling adhesion (Fig. 6, A 
and B), whereas in Mg
2+ alone and Mn
2+ it mediates firm   
adhesion (Fig. 6, C and D). The MIDAS S142A mutation com-
pletely abolishes rolling and firm adhesion in all metal ion 
conditions  (Fig.  6,  A–D).  Compared  with  wild  type,  the   
ADMIDAS D148A mutation in Ca
2+ and Ca
2+ + Mg
2+ mediates 
firm adhesion instead of rolling adhesion (Fig. 6, A and B).   
In contrast, compared with wild type, the SyMBS D237 mu-
tation in Mg
2+ and Mn
2+ mediates rolling adhesion instead of 
firm adhesion (Fig. 6, C and D; Chen et al., 2003). Mutation 
of the extra ADMIDAS residue Glu-354 had a marked effect, 
decreasing rolling adhesion in Ca
2+ and Ca
2+ + Mg
2+, decreas-
ing firm adhesion in Mg
2+ and Mn
2+, and partially convert-
ing firm adhesion to rolling adhesion (Fig. 6, A–D). Mutation 
of extra MIDAS residue Asp-271 had an even more striking 
phenotype. The D271A mutation eliminated rolling adhesion 
in Ca
2+ (Fig. 6 A), greatly diminished rolling in Ca
2+ + Mg
2+ 
(Fig. 6 B), and greatly diminished adhesion in 1 mM Mg
2+  
The net effect of the 4 -propeller substitutions is to 
create a ligand-binding site with an overall different shape than 
those of IIb3 and V3 (Fig. 4, B–D). The 47 ligand-binding 
site has an approximately straight 40 Å–long crevice running 
along the – subunit interface that is 10 Å wide and 10 Å   
deep (Fig. 4 B). In contrast, the crevices in IIb3 and V3 
are narrowed by the specializations described in the proceed-
ing paragraph. Furthermore, the 4 wall completely lacks a 
groove cut through it, which in IIb forms the binding site for 
the N-terminal portion of the fibrinogen gC LGGAKQAGDV 
peptide, which thus binds in a crevice essentially at a right angle 
to the crevice in 47 (Fig. 4 C). The ligand-binding wall of V 
has a groove cut through it that is similar to that in IIb, and the 
W3 4-1 loop protrudes into the V–3 interface near the RGD-
binding site (Fig. 4 D).
The “head-proximal” end of the groove near the W2 2-3 
loop and “leg-proximal” end near the W4 2-3 loop are also 
wider in 47 (Fig. 4, A–D). The 7 SDL creates a wide head-
proximal end because, compared with 3, its disulfide-bonded 
loop with a Pro lacks a 310 helix, and thus extends away from 
 (Fig. 4 B) rather than toward  (Fig. 4, C and D). Moreover, 
together with the protruding Trp-262 residue in IIb and Arg-248 
residue in V, N-glycosylation of Asn-320 in the 6-helix of 
3 blocks the leg-proximal end of the groove site in V3 and 
IIb3 integrins (Fig. 4, C and D).
An extra MIDAS-coordinating residue in 7
Prominent densities at the SyMBS, MIDAS, and ADMIDAS in 
the 7 I domain show that all three sites are occupied by metal 
ions (Figs. 5 A and S3). These derive from the protein prepara-
tion that contained 1 mM Mg
2+ and 1 mM Ca
2+. The coordina-
tion at the MIDAS and ADMIDAS, and the positions in the   
I domain of the 1-1 loop, 1 helix, 6-7 loop, and 7 helix 
Figure 4.  Integrin ligand-binding sites. (A) The loops in the 4 -propeller and 7 I domain that build the ligand-binding site. (B–D) Transparent molecu-
lar surfaces are shown with key residues in stick and loops in cartoon. The surfaces are light gray ( subunit -propeller domains) or wheat ( subunit   
I domains). Ligands are shown in their entirety (47), or key residues of peptides are shown (IIb3 and V3). Metal ions are shown as spheres. (B) 47 
bound to small molecule antagonist. (C) IIb3 bound to fibrinogen g C-terminal peptide (PDB ID 2VDO) (Springer et al., 2008). (D) V3 bound to an 
RGD-mimetic (Xiong et al., 2009).137 Structural specializations of 47 and rolling adhesion • Yu et al.
that Asp-271 regulates the metal ion concentration required 
for adhesion. The D271A mutation raises the EC50 1,000-fold for 
Mg
2+, from 0.1 to 100 mM, and raises the EC50 10-fold for 
Mn
2+, from 0.1 to 1 mM (Fig. 6, E and F). This function of 
Asp271 differs qualitatively from MIDAS residue Ser-142, 
which is indispensible for adhesion even at high metal ion 
concentrations (Fig. 6 G).
Complex with a small antagonist molecule
We  subjected  the  47  headpiece  Fab  complex  to  crystal-
lization in the presence of a small molecule 47 antagonist, 
RO0505376. Crystals grew under similar conditions as in 
(Fig. 6 C). However, in 0.5 mM Mn
2+, D271A had only a small 
effect (Fig. 6 D).
We hypothesized that the concentrations of Mg
2+ and 
Mn
2+ used in these experiments might be sufficient for Mn
2+ 
but not Mg
2+. To test this hypothesis, adhesion in shear flow 
was assayed over a wide range of Mg
2+ and Mn
2+ concentra-
tions  (Fig.  6,  E–G).  Adhesion  of  the  D271A  mutant  was 
nearly absent in 1 mM Mg
2+ and nearly wild type in 1 mM 
Mn
2+ (Fig. 6 F). However, adhesion was almost completely 
recovered  in  100  mM  Mg
2+.  Furthermore,  adhesion  was 
greatly diminished in 0.01 mM and 0.1 mM Mn
2+ compared 
with wild type (Fig. 6, E and F). The titrations demonstrate 
Figure 5.  I domain metal-binding sites and rearrangements upon small molecule antagonist binding. (A and C) 47 metal-binding sites in the absence 
(A) or presence (C) of a small molecule antagonist (with orange carbons). (B and D) Metal-binding sites in IIb3 in the closed conformation (B; PDB acces-
sion no. 3NID; Zhu et al., 2010) and open conformation (C; PDB accession no. 2VDL; Springer et al., 2008). A–D were superimposed on the I domain 
and then displaced vertically or horizontally on the page. (E) RO0505376 binding to 47. (F) RGD peptide binding to IIb3 (PDB accession no. 2VDR; 
Springer et al., 2008). E and F are shown in the same orientation.JCB • VOLUME 196 • NUMBER 1 • 2012   138
co-crystallized with ligand-mimetic compounds (Xiao et al., 
2004; Zhu et al., 2010).
The antagonist binds in the wide cleft between 4 and 
7 with one oxygen of its carboxyl group coordinating the   
MIDAS Mg
2+ (Fig. 4, A and B; and Fig. 5, C and E). The other   
oxygen  of  the  carboxyl  hydrogen  bonds  to  the  backbone   
NH group of residue Asn-143, in the 1-1 loop in the second 
X position of the DXSXS MIDAS motif (Fig. 5 C). The an-
tagonist belongs to the most common class of 4 antagonists, 
the phenylalanine class, and its carboxyl corresponds to the 
phenylalanine -carboxyl group. The phenylalanine -amino 
group hydrogen bonds to the Asn-235 backbone carbonyl, and 
is linked through an amide to a 2,6-dichlorobenzoyl group 
(Fig. 5 E). This group occupies the spacious half of the ligand-
binding cleft toward the SDL (Fig. 4 B). The phenylalanine 
ring is joined at its para position to a third aromatic group, 1,6-
dimethyl-2-oxo-4-trifluoromethyl-pyridine,  which  locates  to 
the middle of the ligand-binding cleft. This positively charged 
aromatic ring makes both van der Waals and - cation bonds 
with 4 residues Tyr-187 and Phe-214, which form an impor-
tant portion of the 4 wall of the binding pocket (Fig. 4 B).   
Furthermore, the 2-oxo group of the pyridine moiety forms 
a strong 2.6 Å hydrogen bond to the side chain of Ser-238 
(Fig. 5 E). Ser-238 projects prominently from the base of the 
ligand-binding groove, and, together with the adjacent depres-
sion at the MIDAS Mg
2+, separates head-proximal and leg-
proximal halves of the cleft (Fig. 4 B). The antagonist has 
few rotatable bonds, and its conformation is further stabilized 
by van der Waals contact between chloro and trifluoromethyl 
groups of the two distal aromatic rings (Fig. 5 E).
Although  47  remains  closed  after  small  molecule 
antagonist binding, some readjustment occurs in the ligand-
binding site (Fig. 5, A and C). These changes are significant 
because  they  are  very  similar  when  the  two  independent 
47–Fab complexes in antagonist-liganded and unliganded 
crystals are compared and are greater than the estimated co-
ordinate error. First, the tip of the 1-1 loop centered at Ser-
144 moves 1 Å closer to the MIDAS Mg
2+ ion. This brings 
the Ser side chain oxygen within 2.1–2.2 Å of the Mg
2+, an 
optimal distance for Mg
2+ coordination (Fig. 5 C). A similar 
1 Å movement of the 1-1 backbone brings the nitrogen of 
residue 143 within hydrogen-bonding distance (3.1 Å) of the 
nonmetal coordinating oxygen of the ligand carboxyl group   
(Fig. 5, A and C). The amount of backbone movement gradu-
ally diminishes to 0.7 or 0.5 Å at the backbones of Asp-147 and 
Asp-148, the side chains of which coordinate the ADMIDAS. 
The  backbone  carbonyl  of  Ser-144  also  coordinates  the   
ADMIDAS Ca
2+, and thus the ADMIDAS Ca
2+ also moves   
0.6 Å (Fig. 5, A and C).
Furthermore, the MIDAS-coordinating alternate confor-
mation of auxiliary MIDAS residue Asp-271 is lost, and now it 
occupies  the  same  position  as  the  noncoordinating  alternate 
conformation  in  the  unliganded  structure,  4  Å  further  away 
from the Mg
2+ (Fig. 5, A and C). The Asp-271 side chain thus 
moves close to Ser-238, and their two side chains together form 
the projection in the middle of the ligand-binding cleft (Fig. 4 B). 
Although there is electrostatic repulsion between the ligand 
the absence of ligand, although with different lattice dimen-
sions (Table 1), and, remarkably, revealed a complex with an 
antagonist with the closed headpiece. This contrasts with the 
IIb3 headpiece, which yields only the open headpiece when 
Figure 6.  Effects of 7 mutations on rolling and firm adhesion of 47 
transfectants on MAdCAM-1 substrates in shear flow. (A–D) Adhesion of 
I domain metal-binding site mutants in 1 mM Ca
2+ (A), 1 mM Ca
2+ +   
1 mM Mg
2+ (B), 1 mM Mg
2+ (C), and 0.5 mM Mn
2+ (D). (E–G) Metal 
ion concentration dependence of adhesion. (H–K) Adhesion of mutants 
in the I domain interface with the hybrid domain in the indicated metal 
ions. Bars show cumulative numbers of firmly adherent and rolling cells at   
2 dyn/cm
2 wall shear stress and error bars show the standard deviation 
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give class averages with as much detail as V3, IIb3, or 
X2 (Takagi et al., 2002; Nishida et al., 2006; Zhu et al., 
2008). Cross-correlations with the IIb3 or V3 ectodomain 
crystal structures fit markedly less well than with EM class 
averages of IIb3 or V3. Furthermore, although X2 has a 
different orientation between the X calf-1 and calf-2 domains 
than in IIb or V (Xie et al., 2010), cross correlation with the 
X2 crystal structure lacking the I domain fit the 47 EM 
class averages no better. Thus, although it clearly has a com-
pact conformation, the orientation between domains in 47 
appears distinct from that in the bent integrins thus character-
ized in crystal structures.
Ectodomain  complexes  with  natalizumab  Fab  revealed 
distinct orientations on the substrate (Fig. 7 B) compared with 
absence of Fab and also appeared to reveal differences in the 
amount of bending at the knees (Fig. 7 B, compare panels 3 and 5). 
carboxyl group and the metal-coordinating conformation of Asp-
271, there is no steric clash, and they bind to opposite rather 
than neighboring positions in the octahedral Mg
2+ coordination 
shell (Fig. 5, A and C).
EM studies on 47 conformation  
and ligand binding
EM allowed our studies to be extended to the complete 47 
ectodomain and complexes with MAdCAM-1 and further Fab 
(Fig. S4). The full 47 ectodomain was expressed with the   
extracellular portions of 4 and 7 (Fig. 1) fused at their   
C termini to flexible linkers followed by disulfide-linked 
ACID-BASE -helical coiled coils that mimic the  and  sub-
unit transmembrane domain association. The complete 47 
ectodomain had a compact rather than extended conformation   
(Fig. 7 A); however, it appeared not as compact and did not 
Figure 7.  EM of the complete ectodomain and headpiece of 47, and complexes with Fab and ligands. (A and B) C-terminally clasped 47 ectodomain 
wild-type (A) or 4 R558A mutant ectodomain complexed with natalizumab Fab (B). (C–G) The 47 R558A mutant headpiece construct complexed with Fab, 
MAdCAM-1, and a small molecule antagonist as indicated, in buffer with 1 mM Ca
2+ and 1 mM Mg
2+, except for the indicated sample in 1 mM Mn
2+. The per-
centage of 47 particles in each state is shown below the representative class averages, and does not sum to 100% because headpiece class averages with-
out bound Fab or MAdCAM-1, or that were poorly resolved, were omitted. (C) Natalizumab. (D) Act-1 Fab. (E) Act-1 Fab and RO0505376. (F) MAdCAM-1.   
(G) MAdCAM-1 and Mn
2+. Schematics depicting orientations in representative class averages are shown to the right. (H and I) Previously published (Takagi 
et al., 2003) representative EM class averages of the 51 headpiece (H) and its complex in Mn
2+ with fibronectin Fn3 domains 7–10 (I). Integrins or com-
plexes were isolated by Superdex S200 gel filtration except the complex between 47 headpiece (0.02 mg/ml) and MAdCAM-1 (0.2 mg/ml) in Ca
2+ + 
Mg
2+, which was formed by mixing the two at room temperature for 30 min and diluting 10-fold just before grid preparation. Bars, 10 nm.JCB • VOLUME 196 • NUMBER 1 • 2012   140
more variation in headpiece orientations on the substrate, includ-
ing side views (Fig. 7 C), as described three paragraphs earlier.
MAdCAM-1 bound to the 47 headpiece with suffi-
cient strength in Mn
2+ for the complex to be isolated by gel 
filtration; binding was weaker in Ca
2+ and Mg
2+, and there-
fore freshly isolated 47 headpiece and MAdCAM-1 were 
mixed together before EM grid preparation. In each metal 
ion condition, a substantial proportion of headpieces did not 
bind MAdCAM-1, resulting in the percentage of complexes 
shown below each panel (Fig. 7). MAdCAM-1 bound at the 
interface between the 4 -propeller and 7 I domain, with 
one and possibly a portion of a second IgSF domain clearly 
projecting out of the interface (Fig. 7, F and G). MAdCAM-1 
was aligned in the same orientation as the 40 Å–long 47 
ligand-binding crevice. The MAdCAM-1–bound 47 head-
piece was in the intermediate conformation in Ca
2+ and Mg
2+ 
(Fig. 7 F); 100% of 47–MAdCAM-1 complexes were in 
the intermediate conformation. Mn
2+ substantially increased 
the  proportion  of  headpieces  with  the  open  conformation 
(Fig. 7 G). Among 47–MAdCAM-1 complexes in Mn
2+, 
64% had the intermediate conformation and 36% had the 
open conformation.
Previously published data on the 51 headpiece (Takagi 
et al., 2003; Luo et al., 2004) provide a direct comparison   
(Fig. 7, H and I). The 51 headpiece alone, either in Ca
2+ or in 
Mn
2+, was found uniformly in a closed conformation (Fig. 7 H).   
When the headpiece was mixed in Mn
2+ with an excess of a 
fragment of fibronectin containing Fn3 domains 7–10 and iso-
lated by gel filtration, 20% of the 51 headpieces bound to Fn3 
7–10, and 100% of the particles were in the open conformation. 
In contrast, all nonliganded 51 headpieces were in the closed 
conformation. Among integrins studied to date, 47 is unique 
not only for its ability to access both the closed and intermediate 
headpiece conformations in the absence of ligand, but also for   
its ability to access both the intermediate and open conforma-
tions in the presence of ligand.
The  comparison  to  51  also  emphasizes  the  distinct   
ligand-binding modalities of 47 and RGD-binding integrins. 
The complexes with 51 show the RGD-bearing Fn3 domain 
10 as a distinct density, which in the orientation on the page 
lies above the 5 -propeller domain and 1 I domain, at their 
interface (Fig. 7 I). In contrast, no such separate density is seen 
for domain 1 of MAdCAM-1, which is consistent with it bind-
ing to a long groove between the 4 -propeller domain and 
the 7 I domain, and the merging of its density with the 
-propeller and I domains (Fig. 7, F and G).
If the closed headpiece mediated rolling, destabilizing the 
closed  I  domain–hybrid  domain  interface  should  decrease 
rolling. In contrast, if an intermediate headpiece conformation 
mediated rolling, destabilizing the closed headpiece should   
increase rolling. We destabilized the closed headpiece with a 
K346A mutation to remove the Lys in the interface, and a 
N260A  mutation  to  remove  the  interacting  N-glycan.  Each   
mutation increased rolling adhesion, without affecting firm ad-
hesion (Fig. 6, H–K). These data support the hypothesis that the 
intermediate headpiece conformation, seen so far only for 47, 
mediates rolling adhesion.
Complexes between natalizumab and only the 47 headpiece 
revealed two different orientations on the substrate with the 
headpiece seen on its side, with the Fab also seen on its side 
(Fig. 7 C, side), or with the headpiece lying flat on the substrate 
and the Fab seen as a flat oval (Fig. 7 C, closed, intermediate, or 
open). Comparison of the side view of the natalizumab Fab 
headpiece complex (Fig. 7 C) to averages of the natalizumab 
Fab ectodomain complex (Fig. 7 B, panels 1, 3, and 5) suggests 
that the latter represents similar side views, and emphasizes that 
density seen in the ectodomain and not headpiece complex class 
averages represent the 47 legs, which appear to vary in orien-
tation with respect to the headpiece.
The 47 headpiece was examined with Fab and with or 
without the antagonist RO0505376 (Fig. 7, C–E) and in the ab-
sence of Fab (Fig. S4). Because Act-1 Fab helped orient the 
headpiece on the substrate, its complexes provided more accu-
rate assessment of headpiece conformation than the headpiece 
alone; however, class averages of the headpiece alone also re-
vealed the intermediate conformation described below (Fig. S4).   
The 4 -propeller domain and 7 I domain in the integrin head 
were resolved as separate densities that were large and small, 
respectively (Fig. 7, D and E). Furthermore, Act-1 Fab bound 
to the smaller  I domain density (Fig. 7, D and E). Two densi-
ties in the -leg correspond to (1) the hybrid domain and (2) the 
PSI and I-EGF1 domains, which are side-by-side in the -leg   
(Fig. 7, D and E). A single density in the -leg corresponds to 
the thigh domain.
We assigned headpiece conformation based on cross-
correlation with the closed headpiece crystal structure and a 
model of the open 47 headpiece, and by visual inspection 
of class averages. By both criteria, 47 can also adopt an   
intermediate conformation of the headpiece that is clearly dis-
tinct from the previously described integrin closed and open 
headpiece conformations. In the absence of RO0505376, the 
majority of the 47 particles had a closed headpiece (Fig. 7 D). 
Almost all remaining particles had an intermediate conforma-
tion of the headpiece: cross-correlation scores with the open 
and closed headpiece were similar, and the -leg showed a 
position intermediate between closed and open (Fig. 7 D). 
Few if any particles exhibited an open headpiece. In the pres-
ence of RO0505376, a substantial proportion of headpieces 
remained  closed,  demonstrating  the  representativeness  of 
the small molecule antagonist-bound closed crystal structure   
(Fig. 7 E). Additionally, a substantial proportion of intermedi-
ate headpieces were present. Moreover, the truly open head-
piece conformation was also seen in presence of RO0505376 
(Fig. 7 E). Distinct densities in the -leg for the hybrid and 
PSI/EGF-1  domains  were  more  evident  for  the  closed  and 
open headpieces than for the intermediate headpiece (Fig. 7, 
D and E), which is consistent with a less well-defined orienta-
tion between the I and hybrid domains in the intermediate 
opening of the headpiece.
Natalizumab binds to the 4 -propeller domain, close to 
its ligand-binding interface with the 7 I domain (Fig. 7 C). 
All three headpiece conformations were seen with natalizumab.   
Natalizumab appears to bind more out of the major plane formed 
by the headpiece domains than Act-1, because its Fab caused 141 Structural specializations of 47 and rolling adhesion • Yu et al.
ligand-binding pocket and may make a direct contribution to 
binding of macromolecular ligands. Residue Glu-354 near the 
ADMIDAS also markedly contributed to rolling adhesion in 
Ca
2+ and firm adhesion in Mg
2+. Functionally, it might be con-
sidered an auxiliary ADMIDAS residue; structurally, it did not 
unambiguously coordinate the ADMIDAS. These findings pro-
vide insights into specializations of 7 for its function in rolling 
and firm adhesion.
In 47, the ligand-binding site is a long, wide groove that 
is open at both ends and is appropriate for lengthwise binding of 
one or two protein domains in which the integrin-binding motif 
is tightly embedded. In contrast, the binding sites at the IIb–3 
and V–3 interfaces are pockets that are closed at one end by 
projections of IIb Trp or V Arg residues and a 3 N-linked 
glycan, and at the other end by V and IIb loops and the   
3 SDL. These differences correlate with recognition by V3 
and IIb3 of peptide motifs, such as RGD, largely independent 
of their macromolecular context. The wall lining the binding 
groove is relatively straight and even in height in 4, whereas 
the IIb and V walls are crooked and notched. These notches 
correlated with binding to peptide fragments in a groove that is 
at right angles to the groove in 47.
Our study provides the first example of how a small mol-
ecule antagonist binds across an integrin – interface outside 
of RGD-recognizing integrins. Early studies showed that an 
I/L-D-T/S motif in domain 1 of MAdCAM-1 and VCAM-1 
(Vonderheide et al., 1994; Viney et al., 1996; Newham et al., 
1997; Green et al., 1999), and a similar LDV motif in the alter-
natively spliced type IIICS segment in fibronectin (Komoriya   
et al., 1991), was important for binding 4 integrins. Notably, both 
RGD and I/L-D-T/S/V motifs contain an Asp that is recognized 
by the I domain MIDAS Mg
2+ ion. The structure of VCAM-1 
revealed that the integrin-binding motif is in a loop between the 
Discussion
Four independent examples in crystals of the 47 headpiece 
yield insights into its flexibility. The -propeller–thigh interface 
enables substantial flexibility, yet maintains close association 
between these neighboring domains. Whereas IIb3 headpiece 
structures show well-defined density for the 3 I-EGF1 and 
PSI domains (Springer et al., 2008; Zhu et al., 2010), in 47, 
density for I-EGF1 was lacking and density for PSI was weak. 
Overall, flexibility at the hybrid domain interface with the 
I-EGF and PSI domains, and at the -propeller–thigh domain 
interface, may make important contributions to encountering 
ligands in rolling adhesion, which requires fast on-rates. In an 
interesting contrast, we found little flexibility, and well-defined 
noncovalent bonds, at the interface in 7 between the I and 
hybrid domains.
We identified a novel auxiliary MIDAS residue, Asp-271. 
It can form a direct coordination to the MIDAS Mg
2+ in one 
of two alternate conformations in the absence of ligand. In 
the presence of RO0505376, it swings away from the Mg
2+, 
perhaps because of electrostatic repulsion by the ligand car-
boxyl group. This auxiliary MIDAS residue is present only in 
the 2, 5, and 7 integrin subunits. Previous 3.5-Å resolution 
X2 crystal structures showed that the homologous residue 
was near the MIDAS, but lacked metal at the I MIDAS, and 
thus could not define whether it was a MIDAS residue (Xie   
et al., 2010).
Our  functional  studies  of  rolling  and  firm  adhesion  in 
shear flow demonstrate that the auxiliary MIDAS residue makes 
a profound contribution to binding MAdCAM-1 by lowering 
the effective concentration of Mg
2+ required from 100 mM to 
0.1 mM. Thus, Asp-271 is indispensable for ligand binding   
at physiological 1 mM Mg
2+ concentrations. Asp-271 is in the 
Figure 8.  VCAM-1 docked to 47. (A) VCAM-1 
domains 1 and 2 (PDB accession no. 1VCA; 
Jones  et  al.,  1995)  were  manually  placed 
in an approximate binding orientation to the 
47 head (-propeller and I domain only, 
no Fab). The orientation was optimized by   
RosettaDock  (Lyskov  and  Gray,  2008).  The 
47 headpiece/Act-1 Fab/RO0505376 struc-
ture  was  superimposed,  and  the  pose  of 
VCAM-1  was  slightly  adjusted  to  align  the   
putative MIDAS-coordinating carboxyl group in 
VCAM-1 to that in RO0505376. (B) Zoomed-
in view of ligand-binding site in A. (C) A repre-
sentative class average of MAdCAM-1 bound 
to the 47 headpiece from Fig. 7 H. Note 
the  similar  orientations  between  the  docked 
VCAM-1 in the model and MAdCAM-1 bound   
to 47. The only difference is that the head-
piece  is  closed  in  the  crystal  structure  and   
in an intermediate conformation when bound 
to MAdCAM-1.JCB • VOLUME 196 • NUMBER 1 • 2012   142
Alignment of VCAM-1 Asp-40 with the -carboxyl group 
of RO0505376 allows assessment of how the other functional 
groups of the phenylalanine class of 4 integrin antagonists 
mimic biological ligands (Fig. 8). Interestingly, the amide-
linked hydrophobic aromatic ring extending toward the head 
end of the groove falls precisely in the position of the key   
hydrophobic Ile-39 side chain that precedes Asp-40 in VCAM-1 
(Fig.  8  B);  this  is  conserved  as  Ile  or  Leu  in VCAM-1, 
MAdCAM-1, and IIICS of fibronectin. Furthermore, a pocket-
like depression here in the 4-7 groove accommodates this 
hydrophobic group (Fig. 4 B). Thus, a key difference between   
I/L-D and RGD motifs is that while the Arg of RGD extends across 
the – interface toward , the Leu of I/L-D extends perpen-
dicularly to the Arg, along the - groove. In contrast, the func-
tion  of  the  phenylalanine  side  chain  of  phenylalanine-based   
4 integrin antagonists is to extend across the – interface, and to 
bring the aromatic ring to which it is connected into contact 
with the 4 wall of the binding groove. Thus, these pharmaco-
phores mimic the thickness of an IgSF domain as it is buried in 
a hydrophobic binding groove.
The RO0505376 antagonist cocrystallized here is closely 
related to the phenylalanine class antagonist firategrast, which 
is currently in clinical trials for multiple sclerosis (Davenport 
and Munday, 2007). The 47 structure and the binding pose of 
cocrystallized antagonist will be invaluable for further develop-
ment of antagonist potency and selectivity for 4l or 47. For 
example, the structure demonstrates that the amide-linked ben-
zoyl ring could be extended toward the SDL at the head end of 
the groove, and that other substituents could interact with   
7 Asp-271. Because 7 and 1 differ markedly in their SDL 
loops, and the 7 auxiliary MIDAS residue Asp-271 is an Ala in 
1, such modifications could improve selectivity for 41, as de-
sired for treatment of multiple sclerosis, or selectivity for 47, 
as desired for treatment of Crohn’s disease.
Humanized Act-1 antibody, vedolizumab, is in clinical 
trials for treatment of ulcerative colitis (Feagan et al., 2005) 
and Crohn’s disease (Feagan et al., 2008). The Act-1 Fab has 
a concave binding site that wraps around the 7 SDL. Interest-
ingly, Ser-231 in the 7 2-3 loop, which hydrogen bonds to 
H3 Trp-104 (Fig. 3 A), is Asn in mouse 7, which introduces an 
N-linked glycosylation site at residue 231. The S231N mutation 
in human 7 loses Act-1 reactivity, and the N231S mutation in 
mouse 7 gains reactivity (Tidswell et al., 1997). Thus, lack of 
glycosylation at this site creates a unique human epitope rec-
ognized by a mouse antibody. However, this glycosylation site 
is distal from the 4-7 groove, and does not affect binding of 
MAdCAM-1 (Tidswell et al., 1997).
Act-1 binds 47 but not 41 or E7 (Schweighoffer   
et al., 1993). This finding, together with our finding that Act-1 
binds only to 7, is likely to be explained by the presence of an 
I domain in E. The I domain is inserted in the -propeller 
W2 4-1 loop, opposite the SDL on the 47 groove (Figs. 3 A   
and 4 A). Superpositions of an I integrin, X2 (Xie et al., 
2010), show a clash of the I domain with Act-1 Fab (Fig. S5).
A further interesting property of Act-1/vedolizumab is 
that it blocks binding of MAdCAM-1 and fibronectin to 47, 
but does not block (Soler et al., 2009), or synergistically enhances 
C and D  strands of IgSF domain 1 (Jones et al., 1995; Wang   
et al., 1995). The conformation of the integrin-binding CD loop 
in VCAM-1 is strongly supported by hydrogen bonds to its 
backbone, and is identical in independent VCAM-1 structures. 
In contrast, the integrin-binding loop in MAdCAM-1 does not 
have a well-defined orientation (Tan et al., 1998; Dando et al., 
2002), and further structures have revealed additional backbone 
conformations (unpublished data).
Therefore, we manually docked domains 1 and 2 of VCAM-1 
with its rigid integrin-binding loop to 47, and were able   
to obtain an unambiguous overall binding orientation (Fig. 8). 
The key Asp side chain carboxyl must lie on the 7 subunit   
side of the ligand-binding groove, which fixes the N-to-C ori-
entation of D1 in the groove. Unlike the other loops in domain 1   
of VCAM-1, the CD loop locates near the middle rather than 
at one of the two ends of the domain; furthermore, although 
it links edge strands in the AGFC and BED -sheets, the CD 
loop is bent so that its Asp is on the GFC side (Fig. 8 B). 
Docking to place the Asp side chain in a similar orientation 
to the RO0505376 carboxyl group places the GFC sheet of 
domain 1 of VCAM-1 in the 4-7 groove (Fig. 8, A and B). 
D2 projects from the head-proximal end of the groove, with its 
CE loop contacting 4 at this end. The finding by mutagenesis 
that the residues in domain 2 important in VCAM-1 binding to 
47 are in the CE loop confirms the docking model (Newham 
et al., 1997). MAdCAM-1 domains 1 and 2 can readily be 
superimposed on those of VCAM-1. The docking orientation 
is strongly supported by the EM projection averages of 47 
headpiece complexes with MAdCAM-1, which show one IgSF   
domain of MAdCAM-1 (which docking suggests is domain 2) 
projecting from the headpiece, on the opposite side from the 
integrin  legs,  and  aligned  with  the  ligand-binding  groove   
(Fig. 8, A and C).
In the docking orientation, the CAM domains that link to 
the membrane—IgSF domains 3–7 in VCAM-1 or a mucin-like 
domain in MAdCAM-1—extend from IgSF domain 2 in one 
direction, and the integrin legs extend away in the other direc-
tion. This geometry is not only ideal for cell adhesion but is also 
force-resistant because tensile force applied to the complex as it 
mediates adhesion in shear flow is aligned with the binding 
groove, and a large number of interactions along the groove 
would have to be broken at once for receptor–ligand dissocia-
tion to occur.
Our structure of 47 and the proposed docking model 
are compatible with previous mutational studies on 4. In the 
4 W3 2-3 loop, which is central in the ligand-binding site, 
Tyr-187, which forms the ligand-binding wall opposite the 
MIDAS and contacts RO0505376, is required for 41 bind-
ing to VCAM-1 and the IIICS segment of fibronectin (Irie et al.,   
1995). Moreover, exchange of loops between the 4 and 5 
subunits at the head end of the - groove (W2 2-3) and 
leg end of the groove (W4 2-3) blocked 41 binding to 
VCAM-1 and a fibronectin IIICS peptide (Irie et al., 1997). 
These results are compatible with contact of protein ligands 
with an extensive interface along the – groove as proposed 
here, and suggest extension of this concept to the 41 inter-
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by the closed headpiece, mutational destabilization of the closed 
headpiece would decrease rolling, whereas the opposite was 
found. Furthermore, if there were no intermediate state, desta-
bilization of the closed headpiece would increase firm adhe-
sion; however, firm adhesion was unaffected. Thus, mutational 
enhancement of rolling and lack of effect on firm adhesion 
provide strong support for the concept that the intermediate 
headpiece conformation mediates rolling adhesion. We also 
found  that  the  47  headpiece  could  be  crystallized  in  the 
closed headpiece conformation in the presence of a small mol-
ecule antagonist, which is consistent with EM results. How-
ever, the antagonist induced movements in the MIDAS 1-1 
loop, which may in part mimic movement toward the inter-
mediate headpiece conformation.
Thus, data now suggest that the rolling phase of adhesion 
mediated by the MAdCAM-1 complex with 47 corresponds 
to an intermediate state of the 47 headpiece, and the firm 
phase corresponds to the open state of the headpiece. Detailed 
understanding of these states must await crystal structures of 
complexes of MAdCAM-1 and 47. The important point bio-
logically is that ligand binding does not induce the open head-
piece conformation with high affinity for ligands, as seen with 
RGD-binding integrins that mediate firm adhesion; therefore, 
the intermediate conformation can persist after ligand binding, 
so that 47 can mediate rolling adhesion. This specialization of 
47 enables rolling versus firm adhesion to be regulated by 
signals from within the cell. Thus, physiological signals en-
countered by a leukocyte rolling through 47 on endothelium, 
such as those received by G protein–coupled chemokine recep-
tors, can activate inside-out signals that cause 47 headpiece 
opening, and activate firm adhesion through 47 as a prelude 
to lymphocyte transendothelial migration.
Materials and methods
Protein expression, purification, and crystallization
Soluble 47 headpiece and ectodomain were prepared similarly to X2 
(Xie et al., 2010). In brief, the 4 subunit cloned in pcDNA3.1/Hygro() 
was followed by a tobacco etch virus (TEV) site, the ACID coiled-coil, and a 
Strep-II tag. The 7 subunit cloned in pEF1-puro was followed by a TEV site, 
the BASE coiled-coil, and a His tag. Proteins expressed in CHO-Lec3.2.8.1 
cells were purified using Ni-NTA and Strep-Tactin affinity chromatography. 
Natalizumab was from S. Goelz (Biogen Idec, Cambridge, MA). Antibody 
Act-1 and further natalizumab were from E. Fedyk (Millenium: The Takeda 
Oncology Co., Cambridge, MA). The headpiece was stabilized with Act-1 
Fab (1:3 molar ratio) and cleaved with TEV protease and EndoH at room 
temperature overnight. The mixture was passed through Ni-NTA resin and 
further purified by gel filtration. The 47–Act-1 Fab complex was concen-
trated to 3.6 mg/ml in 10 mM Tris, pH 7.5, 0.15 M NaCl, 1 mM CaCl2, 
and 1 mM MgCl2. RO0505376 was added to a final concentration of   
0.5 mM. Crystals were grown in 0.1 M Tris, pH 8.5, 0.1 M NaCl, and 8–10% 
polyethylene glycol (PEG) 20,000 at 4C°. To incorporate Se-Met in pro-
tein, cells were washed with PBS supplemented with 1% dialyzed FCS, 
incubated with methionine-free -MEM (SAFC Biosciences) supplemented 
with 50 mg/l l-Se-Met (Sigma-Aldrich) and 10% dialyzed FCS, replaced 
with the same medium after 6 h, and cultured for 4 d (Xie et al., 2010). 
Crystals were cryoprotected by first increasing the PEG 20,000 to 15%. 
Then PEG 400 or 2-methyl-2,4-pentaneidiol for native or RO0505376 
crystals, respectively, was added in 5% increments to 30%. RO0505376 
was from J. Tilley (Roche, Nutley, NJ).
Structure determination
Structures were determined in three lattices (Table 1). Phases for a 3.5-Å 
MAD dataset in lattice B were solved with SHARP (Vonrhein et al., 2007). 
(Schweighoffer et al., 1993), binding to VCAM-1. Consistent 
with this finding, our model of docked VCAM-1 shows that it 
fits in the 4-7 groove without clashing with, but is in close 
proximity to, Act-1 Fab (Fig. 8). In contrast to the CE loop 
in domain 2 of VCAM-1, MAdCAM-1 contains a much longer 
“charged antenna” DE loop in domain 2 (Tan et al., 1998; 
Dando et al., 2002), which is disordered in crystal structures,   
and important in binding to 47 (Green et al., 1999). Super-
position of MAdCAM-1 on docked VCAM-1 locates the charged 
antenna near the 7 SDL, and explains selective blocking by 
Act-1/vedolizumab. Basic patches of residues on the SDL of   
7 and in the W2 2-3 loop of the 4 -propeller domain 
(Fig. 3 B) are present in the 4-7 groove for interaction with 
the MAdCAM-1 charged antenna.
Natalizumab to the 4 integrin subunit is in clinical use 
for treatment of relapsing multiple sclerosis and Crohn’s disease 
(Miller et al., 2003; Sandborn et al., 2005). EM shows that this 
antibody binds to the 4 -propeller domain close to the 4-7 
groove. The mouse precursor antibody to natalizumab, termed 
an100226m (Kent et al., 1995) or TY21/6 (Newham et al., 
1998), is similar to 4 antibodies to B1 and B2 epitopes (Pulido 
et al., 1991; Newham et al., 1998) that require human 4 resi-
dues 152–203 in -propeller blade W3 for recognition (Schiffer 
et al., 1995). This is consistent with localization by EM of the 
natalizumab Fab-binding site adjacent to the 4-7 groove. EM 
further demonstrated that neither Act-1 nor natalizumab inhib-
ited ligand binding by stabilizing the integrin headpiece in the 
closed conformation, in contrast to some 1 and 2 antibodies 
(Luo et al., 2004; Chen et al., 2010).
The 47 ectodomain has a less compact bent conforma-
tion than seen for V3, IIb3, X2, and L2 integrins (Takagi 
et al., 2002; Nishida et al., 2006; Zhu et al., 2008), and has a 
novel intermediate conformation of the headpiece. Previously, 
V3, IIb3, X2, L2, and 51 integrins have shown only 
closed and open headpiece conformations (Takagi et al., 2002, 
2003; Luo et al., 2004; Xiao et al., 2004; Nishida et al., 2006; 
Xiong et al., 2009; Chen et al., 2010; Zhu et al., 2010). Closed, 
intermediate, and open conformations of the 47 headpiece 
were all seen in the presence of saturating concentrations of a 
small molecule antagonist. Moreover, the same small molecule 
cocrystallized with Act-Fab and 47 headpiece in the closed 
conformation. These results strongly contrast with the IIb3 
headpiece, which crystallizes in the open conformation in the 
presence of RGD-like antagonists, and in the closed conforma-
tion in their absence (Xiao et al., 2004; Zhu et al., 2010). Fur-
thermore, when complexed with MAdCAM-1, 47 displayed 
intermediate as well as open headpiece conformations. This 
contrasts with the 51 headpiece, which was always open when 
bound to a fibronectin fragment (Takagi et al., 2003).
Previously, the rolling and firm phases of 47 adhesion 
were proposed to, respectively, correlate with the low-affinity, 
closed-headpiece, and high-affinity, open-headpiece states 
seen with other integrins (Chen et al., 2003, 2004). The obser-
vation that 47 is either intermediate or open and not closed 
when complexed with MAdCAM-1, together with mutational 
studies, now strongly suggests that rolling is mediated by the 
intermediate headpiece conformation. If rolling were mediated JCB • VOLUME 196 • NUMBER 1 • 2012   144
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Phases for a 3.6 Å single-wavelength anomalous dispersion (SAD) dataset 
in lattice A were first obtained by molecular replacement using the Fab 
complex model from lattice B. PHASER (McCoy et al., 2007) was then 
used to calculate experimental phases for lattice A based on 24 Se atoms. 
The SAD phases were transferred to the 3.15 Å native data in this lattice. 
Multicrystal averaging improved and extended the phases. A better model 
was built, and new domain masks calculated. Multicrystal, multidomain 
averaging was performed once more. The resulting model was used with 
molecular replacement to solve the complex with RO0505376 in lattice C. 
Models were iteratively improved by building with COOT (Emsley and 
Cowtan, 2004), refinement with PHENIX (Adams et al., 2002), and valida-
tion with MOLPROBITY (Davis et al., 2007).
Negative stain EM
47 ectodomain or headpiece proteins, with or without MAdCAM-1, Fab, 
or RO0505376, were loaded on a gel filtration column (Superdex 200 
HR; GE Healthcare) pre-equilibrated with Tris-buffered saline, 1 mM CaCl2 
and 1 mM MgCl2, or 1 mM MnCl2. When present, RO0505376 was also 
added to the running buffer (0.5 mM). Peak fractions were adsorbed to 
glow-discharged carbon-coated copper grids and stained with uranyl for-
mate, and images acquired with an electron microscope (Tecnai 12; FEI) 
at 120 kV and a nominal magnification of 67,000. Particles were inter-
actively picked using BOXER in EMAN (Ludtke et al., 1999). Grid location 
coordinates were converted to SPIDER (Frank et al., 1996) format and 
used in windowing particles to create a boxed image stack. Each image in 
the stack was normalized to a mean intensity of 0 and SD of 50. Normal-
ized images were subjected to 10 iterations of centering, multivariate sta-
tistical analysis, K-means classification, class averaging, and multireference 
alignment, with the class averages used as input references for multirefer-
ence alignment in the next iteration (Mi et al., 2011).
Flow chamber experiments
7 mutations were generated using KOD-Plus-Mutagenesis (Toyobo Co.). 
Wild-type human 7 cDNA in vector pcDNA3.1/Hygro(–) (Invitrogen) 
was used as the template. All mutations were confirmed by DNA sequenc-
ing. 293T cells were transiently transfected with 4 and 7 cDNA using 
calcium phosphate precipitates. Adhesion in a parallel wall flow chamber 
on a plastic substrate coated with a human MAdCAM-1 Fc chimera was 
performed exactly as described previously (Chen et al., 2003). In brief, 
cells were pumped into a flow chamber mounted on a Petri dish coated 
with 10 µg/ml huMAdCAM-1/Fc, and allowed to accumulate for 30 s at 
0.3 dyn/cm
2 and 10 s at 0.4 dyn/cm
2. Then, shear stress was increased 
every 10 s from 1 dyn/cm
2 up to 32 dyn/cm
2, in twofold increments. The 
number of cells remaining bound at the end of each 10-s interval and the 
rolling velocity were determined.
Online supplemental material
Fig. S1 shows the six integrin  subunit families, and variation in known li-
gand binding loops in their -propellers. Fig. S2 shows structure-based se-
quence alignment of structurally defined integrins with 47. Fig. S3 shows 
density for I domain metal ions and Asp-271. Fig. S4 shows all class aver-
ages from negative stain EM. Fig. S5 shows superimposition of X2 on the 
47 headpiece–Act-1 Fab complex. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201110023/DC1.
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